Ultrasound-guided renal artery administration of angiopoietin-1 RNA therapy slows the progression of preclinical WT1 glomerular disease

Mutations in the transcription factor Wilms Tumour 1 (WT1) are one of the leading causes of congenital glomerular disease, characterised by severe urinary protein loss and glomerular scarring. Currently no disease modifying therapies exist for WT1 glomerulopathies and affected children rely on dialy